NEW YORK, July 31 – Celera Diagnostics has sought marketing approval from the FDA for its HIV drug resistance system, the company announced Tuesday.

The premarket notification submission was made for Celera Diagnostics’ ViroSeq HIV-1 Genotyping System, an in vitro  method for detecting drug resistance in the HIV-1 virus genome.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.